Virtual Library

Start Your Search

Youcai Zhu



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 2
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      10P - The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations (ID 156)

      12:30 - 13:00  |  Author(s): Youcai Zhu

      • Abstract
      • Slides

      Background

      Although roles of JAK2 mutations in myeloproliferative neoplasms (MPN) are well established, roles of JAK2 mutations in the pathogenesis of non-small cell lung cancer (NSCLC) remain unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring JAK2 mutations.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      A total of 766 patients with non-small-cell lung cancer were recruited between July 2012 and December 2016. The status of JAK2 mutations and other genes were detected by next generation sequencing.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      JAK2 gene mutation rate was 2.35% (18/766) in non-small cell lung cancer, including V617F (3 patients), L43I (2 patients), D768H (1 patient), G1066A (1 patient), W1020C (1 patient), S465R (1 patient), Q21E (1 patient), T842A (1 patient), C452* (1 patient), I404M (1 patient), P708Q (1 patient), S488* (1 patient), S1035L (1 patient), V387L(1 patient) and E575* (1 patient), and median overall survival (OS) for these patients was 19.0 months. Among them, all patients were JAK2 gene with co-occurring mutations. Briefly, patients with (n = 4) or without (n = 14) co-occurring EGFR mutations had a median OS of 23.0 months and 13.0 months respectively (P = 0.05); patients with (n = 11) or without (n = 7) co-occurring TP53 mutations had a median OS of 20.0 months and 7.0 months respectively (P = 0.01); patients with (n = 3) or without (n = 15) co-occurring ARID1A mutations had a median OS of 20.0 months and 13.0 months respectively (P = 0.32); patients with (n = 6) or without (n = 12) co-occurring KRAS mutations had a median OS of 11.5 months and 20.0 months respectively (P = 0.25).

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      TP53 accompanied mutations might play a good prognosis in JAK2 gene mutation NSCLC. Next generation sequencing provides a simplified strategy and reasonably high detection rate for JAK2 mutation, which suggested application of the strategies into clinical molecular diagnostics.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      14P - The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis (ID 155)

      12:30 - 13:00  |  Presenting Author(s): Youcai Zhu

      • Abstract
      • Slides

      Background

      MET exon 14 skipping is a potential driver alteration in lung cancer targetable. Treatment with crizotinib can cause dramatic responses in patients whose cancers have MET exon 14 skipping. The current study was aiming to determine the clinical and pathological characteristics in non-small cell lung cancers (NSCLC).

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      A total of 2926 patients with NSCLC were recruited between July 2012 and 2015. The status of MET exon 14 skipping and other genes were detected by next generation sequencing.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      MET exon 14 skipping rate was 1.06% (31/2926) in NSCLC, including X1009_spilce (10 patients), X963_spilce (6 patients), D1010H (5 patients), D1010N (3 patients), X1008_spilce (1 patient), X1006_spilce (1 patient), X1007_spilce (1 patient), D1010Y (1 patient), Y1003S (1 patient), D1002G (1 patient), P1008A (1 patient). Among them, EGFR mutations+ MET skipping [7 patients (2 patients with 19 del+ 5 patients with L858R)], ALK fusion+ MET skipping (2 patients) and ROS1 fusion+ MET skipping (1 patient).

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      MET exon 14 skipping defined a new molecular subset of NSCLC with identifiable clinical characteristics. The therapeutic crizotinib might be an alternative treatment for patients with MET exon 14 skipping NSCLC.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    Mini Oral session I (ID 60)

    • Event: ELCC 2019
    • Type: Mini Oral session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 08:00 - 08:50, Room A
    • +

      114O - Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study (ID 157)

      08:00 - 08:50  |  Presenting Author(s): Youcai Zhu

      • Abstract
      • Presentation
      • Slides

      Background

      Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR sensitizing mutations or T790M mutation. However, approximately 5% to 15% of patients with non-small-cell lung cancer (NSCLC) with EGFR T790M mutation has primary resistance to osimertinib treatment. The underlying mechanism is unknown.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      A total of 117 patients with stage IIIb-IV EGFR-T790M NSCLC were undergoing tumor biopsies or blood withdrawing by the time of primary or acquiring to osimertinib, including FFPE samples, serum samples and serous effusions. We used targeted NGS to detect genes status of patients.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      Among 117 patients treated with osimertinib, 82.91% (97/117) developed acquired resistance, and 7.69% (9/117) had primary resistance. Using the specimens at the baseline, there were 3 (33.33%) patients with MET amplification, 1 (11.11%) patient with BCL2L11 loss (BIM deletion polymorphism), 1 (11.11%) patient with ERBB2 amplification, 1 (11.11%) patient with PTEN mutation, 1 (11.11%) patient with EZH2 mutation, and 2 (22.22%) patients with unknown status.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      The mechanisms of primary resistance to EGFR-T790M may be highly heterogeneous. BCL2L11 loss, MET amplification, ERBB2 amplification, PTEN mutations, EZH2 mutations might contribute to molecular mechanisms of primary resistance to osimertinib in EGFR-T790M NSCLC. Further investigations are warranted to overcome these primary resistances.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.